- Molecular NameImidapril
- SynonymNA
- Weight405.451
- Drugbank_IDN/A
- ACS_NO89371-37-9
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)0.73
- pkaN/A
- LogD (pH=7, predicted)-3.26
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-1.17
- LogSw (predicted, AB/LogsW2.0)16.56
- Sw (mg/ml) (predicted, ACD/Labs)0.16
- No.of HBond Donors2
- No.of HBond Acceptors9
- No.of Rotatable Bonds10
- TPSA116.25
- StatusN/A
- AdministrationN/A
- PharmacologyAn ACE inhibitor.
- Absorption_value70.0
- Absorption (description)Imidapril is rapidly absorbed
- Caco_2N/A
- Bioavailability20.0
- Protein binding85.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmExtensively metabolised in the liver, by de-esterification, to its pharmacologically active diacid metabolite, imidaprilat and a number of minor metabolites. Peak concentrations of the drug are seen after 2 h and the active metabolite, 7 to 8 h after administration.
- Half life2 h (imidapril); 8 h (imidaprilat)
- ExcretionIt is excreted in urine mainly as the metabolites.
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityThe most frequently adverse effects were cough, dizziness, fatigue, somnolence, dyspepsia and vomiting
- LD50 (rat)N/A
- LD50 (mouse)N/A